- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06062420
Fase 2-plattformstudie av nye immunterapikombinasjoner som førstelinjebehandling hos deltakere med PD-L1 positiv tilbakevendende/metastatisk plateepitelkarsinom i hode og nakke
En fase 2, randomisert, åpen plattformstudie ved bruk av en masterprotokoll for å evaluere nye immunterapikombinasjoner som førstelinjebehandling hos deltakere med tilbakevendende/metastaserende PD-L1 positivt plateepitelkarsinom i hode og nakke
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Capital Federal, Argentina, C1181ACH
- GSK Investigational Site
-
Ciudad Autonoma de Bueno, Argentina, C1056ABI
- GSK Investigational Site
-
Córdoba, Argentina, 5000
- GSK Investigational Site
-
Florida, Argentina, B1602DQD
- GSK Investigational Site
-
Mendoza, Argentina, M5500AYB
- GSK Investigational Site
-
San Juan, Argentina, 5400
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Santo André, Brasil, 09060-650
- GSK Investigational Site
-
São Paulo, Brasil, 01246-000
- GSK Investigational Site
-
São Paulo, Brasil, 01221-020
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- GSK Investigational Site
-
Edmonton, Alberta, Canada, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- GSK Investigational Site
-
-
-
-
-
Herlev, Danmark
- GSK Investigational Site
-
-
-
-
-
Turku, Finland, 20520
- GSK Investigational Site
-
-
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06511
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- GSK Investigational Site
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110-1010
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- GSK Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Frankrike, 33075
- GSK Investigational Site
-
Caen, Frankrike, 14075
- GSK Investigational Site
-
Marseille, Frankrike, 13005
- GSK Investigational Site
-
Paris, Frankrike, 75005
- GSK Investigational Site
-
Rouen, Frankrike, 76038
- GSK Investigational Site
-
Villejuif, Frankrike, 94805
- GSK Investigational Site
-
-
-
-
-
Haidari - Athens, Hellas, 12462
- GSK Investigational Site
-
Marousi, Hellas
- GSK Investigational Site
-
-
Central Macedonia
-
Panórama, Central Macedonia, Hellas, 552 36
- GSK Investigational Site
-
-
-
-
-
Bari, Italia, 70124
- GSK Investigational Site
-
Bologna, Italia, 40139
- GSK Investigational Site
-
Florence, Italia, 50134
- GSK Investigational Site
-
Genova, Italia, 16132
- GSK Investigational Site
-
Milan, Italia, 20133
- GSK Investigational Site
-
Naples, Italia, 80131
- GSK Investigational Site
-
Novara, Italia, 28100
- GSK Investigational Site
-
Padova, Italia, 35128
- GSK Investigational Site
-
Roma, Italia, 00168
- GSK Investigational Site
-
Roma, Italia, 00144
- GSK Investigational Site
-
-
MI
-
Rozzano, MI, Italia, 20089
- GSK Investigational Site
-
-
-
-
-
Aichi, Japan, 464-8681
- GSK Investigational Site
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Hyōgo, Japan, 650-0017
- GSK Investigational Site
-
Osaka, Japan, 541-8567
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
Shizuoka, Japan, 411-8777
- GSK Investigational Site
-
Tokyo, Japan, 104-0045
- GSK Investigational Site
-
-
-
-
-
Oslo, Norge, 0379
- GSK Investigational Site
-
-
-
-
-
Bielsko-Biala, Polen, 43-300
- GSK Investigational Site
-
Katowice, Polen, 40-514
- GSK Investigational Site
-
Krakow, Polen, 31-826
- GSK Investigational Site
-
Przemyśl, Polen, 37-700
- GSK Investigational Site
-
Siedlce, Polen, 08-110
- GSK Investigational Site
-
Warsaw, Polen, 04-141
- GSK Investigational Site
-
-
-
-
-
Almada, Portugal, 2801-951
- GSK Investigational Site
-
Lisbon, Portugal, 1649-035
- GSK Investigational Site
-
Porto, Portugal, 4099-001
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
-
-
-
-
Brasov, Romania, 500283
- GSK Investigational Site
-
Bucharest, Romania, 020142
- GSK Investigational Site
-
Bucharest, Romania, 022328
- GSK Investigational Site
-
Bucharest, Romania, 030171
- GSK Investigational Site
-
Bucharest, Romania, 30463
- GSK Investigational Site
-
Craiova, Romania, 200542
- GSK Investigational Site
-
Floreşti, Romania, 407280
- GSK Investigational Site
-
Iași, Romania, 700483
- GSK Investigational Site
-
Oradea, Romania, 410469
- GSK Investigational Site
-
Piteşti, Romania, 110283
- GSK Investigational Site
-
Suceava, Romania, 720214
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spania, 08035
- GSK Investigational Site
-
Barcelona, Spania, 08907
- GSK Investigational Site
-
Barcelona, Spania, 08023
- GSK Investigational Site
-
Jaén, Spania, 23007
- GSK Investigational Site
-
Madrid, Spania, 28041
- GSK Investigational Site
-
Madrid, Spania, 28040
- GSK Investigational Site
-
Madrid, Spania, 28034
- GSK Investigational Site
-
Madrid, Spania, 28010
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Spania, 28223
- GSK Investigational Site
-
Salamanca, Spania, 37007
- GSK Investigational Site
-
Santander, Spania, 39008
- GSK Investigational Site
-
Valencia, Spania, 46009
- GSK Investigational Site
-
Zaragoza, Spania, 50009
- GSK Investigational Site
-
-
-
-
-
Daegu, Sør -Korea, 42601
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Sør -Korea, 13620
- GSK Investigational Site
-
Seoul, Sør -Korea, 138-736
- GSK Investigational Site
-
Seoul, Sør -Korea, 03722
- GSK Investigational Site
-
Suwon Kyunggi-do, Sør -Korea, 443-721
- GSK Investigational Site
-
-
-
-
-
Changhua, Taiwan, 500
- GSK Investigational Site
-
Tainan, Taiwan, 704
- GSK Investigational Site
-
Taipei, Taiwan, 11217
- GSK Investigational Site
-
Taipei, Taiwan, 10002
- GSK Investigational Site
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06100
- GSK Investigational Site
-
Istanbul, Tyrkia (Türkiye), 34662
- GSK Investigational Site
-
Izmir, Tyrkia (Türkiye), 35040
- GSK Investigational Site
-
-
-
-
-
Aachen, Tyskland, 52074
- GSK Investigational Site
-
Berlin, Tyskland, 12203
- GSK Investigational Site
-
Giessen, Tyskland, 35392
- GSK Investigational Site
-
Hamburg, Tyskland, 20246
- GSK Investigational Site
-
Regensburg, Tyskland, 93053
- GSK Investigational Site
-
Ulm, Tyskland, 89075
- GSK Investigational Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60488
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Tyskland, 45122
- GSK Investigational Site
-
-
-
-
-
Győr, Ungarn, 9024
- GSK Investigational Site
-
Kecskemét, Ungarn, 6000
- GSK Investigational Site
-
Pécs, Ungarn, 7624
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have histologically or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology)
- Has measurable (target) disease based on RECIST 1.1 as determined by the investigator.
- Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh biopsy is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumor. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable.
- Has tumor Programmed death ligand 1 (PD-L1) expression
- If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results
Exclusion Criteria:
- Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways.
- Participants with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
- Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major vessel [carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as arteriovenous fistula).
- Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC
- Participants with any carcinomatous meningitis or leptomeningeal spread and those with uncontrolled or symptomatic Central Nervous System (CNS) metastases
- Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dostarlimab monoterapi
|
Dostarlimab will be administered. |
|
Eksperimentell: Delstudie 1: Dostarlimab og Belrestotug
|
Dostarlimab will be administered. Belrestotug will be administered. |
|
Eksperimentell: Delstudie 2: Dostarlimab og nelistotug
|
Dostarlimab will be administered. Nelistotug will be administered. |
|
Eksperimentell: Delstudie 3: Dosarlimab og Belrestotug og nelistotug
|
Dostarlimab will be administered. Belrestotug will be administered. Nelistotug will be administered. |
|
Eksperimentell: Substudie 4: Dostarlimab og Remzistotug
|
Dostarlimab will be administered. Remzistotug will be administered. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy
Tidsramme: Up to approximately 24 months
|
Confirmed ORR is defined as the percentage of participants achieving confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment. |
Up to approximately 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antall deltakere med TEAE som fører til doseendringer eller seponering av studieintervensjon
Tidsramme: Opptil ca 24 måneder
|
Opptil ca 24 måneder
|
|
Antall deltakere med klinisk signifikante funn i vitale tegn, elektrokardiogram (EKG) og laboratorietestparametre
Tidsramme: Opptil ca 24 måneder
|
Opptil ca 24 måneder
|
|
Antall deltakere med akutte behandlingsbivirkninger (AEs), behandlingsfremvoksende alvorlige bivirkninger (SAE) og behandlingsfremvoksende bivirkninger av spesiell interesse (AESI)
Tidsramme: Opptil ca 24 måneder
|
Opptil ca 24 måneder
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 219885
- 2023-503428-24 (Registeridentifikator: CTIS)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Tilgangskriterier for IPD-deling
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .